Penka Petrova - Nov 17, 2021 Form 4 Insider Report for Trillium Therapeutics Inc. (TRIL)

Role
Chief Development Officer
Signature
/s/ James Parsons, Attorney-in-Fact
Stock symbol
TRIL
Transactions as of
Nov 17, 2021
Transactions value $
$0
Form type
4
Date filed
11/19/2021, 12:24 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRIL Stock Option (Right to Buy) Disposed to Issuer $0 -38.8K -100% $0.00* 0 Nov 17, 2021 Common Shares 38.8K $15.27 Direct F1, F5
transaction TRIL Stock Option (Right to Buy) Disposed to Issuer $0 -4.57K -100% $0.00* 0 Nov 17, 2021 Common Shares 4.57K $9.65 Direct F2, F5
transaction TRIL Stock Option (Right to Buy) Disposed to Issuer $0 -49.5K -100% $0.00* 0 Nov 17, 2021 Common Shares 49.5K $3.34 Direct F3, F5
transaction TRIL Stock Option (Right to Buy) Disposed to Issuer $0 -84K -100% $0.00* 0 Nov 17, 2021 Common Shares 84K $0.30 Direct F4, F5
transaction TRIL Stock Option (Right to Buy) Disposed to Issuer $0 -140K -100% $0.00* 0 Nov 17, 2021 Common Shares 140K $12.03 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Penka Petrova is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The exercise price of these options is $19.333 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.
F2 The exercise price of these options is $12.22 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.
F3 The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.
F4 The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.
F5 On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.